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ABSTRACT
Objective: The purpose of this study was to compare the
costs and cost-effectiveness (C/E) of early hepatitis C
virus (HCV) RNA testing (alternative-US recommenda-
tions) after occupational exposure to HCV with existing
follow-up strategies: (1) French, anti-HCV antibodies and
alanine transaminase (ALT) activity at months 1, 3 and 6;
(2) European, monthly ALT activity for 4 months and anti-
HCV antibodies at month 6; (3) and baseline-US, anti-HCV
antibodies and ALT activity at month 6.
Methods: A decision tree simulated each strategy for
7300 healthcare workers (HCWs) exposed to HCV each
year in France, taking into account the impact of early
diagnosis on the response to antiviral treatment and the
deterioration of HCW quality of life after exposure.
Results: For a HCV transmission risk of 0.5% after
exposure, the French strategy led to the highest costs/
person (J181.40) and the baseline-US strategy to the
lowest (J126.60) (J178.50) for alternative-US). The
shortest mean time to HCV infection diagnosis (1 month)
and the lowest number of chronic hepatitis C (CHC)
patients (1.9/7300 HCWs exposed) was obtained with
the alternative-US strategy (vs 6 months and 7.9 CHC,
respectively with baseline-US). Compared with the
alternative-US, the French strategy was associated with
higher costs and lower utilities, and the European with a
higher incremental C/E ratio. Compared with the baseline-
US strategy, the alternative-US strategy C/E ratio was
J2020 per quality-adjusted life year saved.
Conclusion: In HCWs exposed to HCV, a strategy based
on early HCV RNA testing shortens the period during
which the HCW’s wait for his HCV status, leads to lower
risk of progression to CHC and is reasonably cost-
effective.
Infection by hepatitis C virus (HCV) is an
important occupational hazard for healthcare
workers (HCWs). In France, in 2004, 41 276
accidental blood exposures occurred in hospitals,
58.7% of which were percutaneous injuries.
1 Of
these cases, 6.2% occurred to anti-HCV antibody-
positive source patients and 24.1% to source
patients whose status was not known but who
were considered as potentially anti-HCV antibody
positive. In the USA, 1 385 280 sharp injuries were
estimated to occur annually, and 22 000 HCWs
were exposed to at least one percutaneous injury
with a sharp object contaminated with HCV
2
(http://www.who.int/quantifying_ehimpacts/
publications/en/sharps.pdf).
Different follow-up schedules for occupational
HCV detection have been recommended in
different countries. Whereas European guidelines
recommend alanine transaminase (ALT) monitor-
ing alone,
3 French and baseline-US guidelines are
based on anti-HCV antibody and ALT monitor-
ing,
45but alternative-US guidelines propose HCV
RNA testing at 4–6 weeks if earlier diagnosis of
HCV infection is desired. The risk of transmission
is first determined by the status of the source
patient: when the occupational exposure involves
an HCV RNA-negative source patient, the risk is
considered to be zero; when the source patient is
HCV RNA-positive, it is estimated at 0–10.3%,
6–16
with an average rate of 0.5%.
11 17 The results of a
recent case–control study conducted in five
European countries suggested that after occupa-
tional exposure to HCV, assessment of the risk of
transmission should take into account the severity
of the injury and the device involved.
18 Our
hypothesis is that follow-up schedules should be
tailored to the HCW’s risk of HCV seroconversion
after percutaneous exposure.
In this study, using a cost-effectiveness (C/E)
analysis, we compared the three existing follow-up
strategies recommended in France, Europe and the
USA after occupational exposure to HCV, with a
strategy based on early HCV RNA testing, accord-
ing to the risk of HCV transmission.
MATERIALS AND METHODS
Study design
We designed a decision analysis model to compare
in HCWs exposed to an HCV-positive source the
three existing strategies of follow-up and a strategy
based on early HCV RNA testing:
c Strategy 1: monitoring of anti-HCV antibodies
and ALT activity at months 1, 3 and 6 after
HCV exposure, and HCV RNA testing to
confirm positive anti-HCV antibody results
and/or ALT elevation (French recommenda-
tions).
4
c Strategy 2: monthly monitoring of ALT activ-
ity for 4 months after HCV exposure, and of
anti-HCV antibodies at month 6, and HCV
RNA testing to confirm ALT elevation or
positive anti-HCV antibody results (European
recommendations).
3
c Strategy 3: anti-HCV antibody and ALT
activity monitoring at month 6 after HCV
exposure, and HCV RNA testing to confirm
positive anti-HCV antibody results (baseline-
US recommendations).
5
c Strategy 4: HCV RNA testing 1 month after
HCV exposure (alternative-US recommenda-
tions), as proposed by US recommendations if
earlier diagnosis of HCV is desired.
5
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Gut 2009;58:105–110. doi:10.1136/gut.2007.145516 105Baseline anti-HCV antibodies and ALT activity were deter-
mined, but, as they were identical for the four strategies, they
were not taken into account in this analysis. When the HCV
RNA test was negative during follow-up, a second HCV RNA
test was requested to confirm the absence of HCV infection,
because undetectable HCV RNA at one time point does not
exclude the possibility of HCV infection.
19 20 When the HCV
RNA test was positive, a second HCV RNA test was required
before treatment administration.
The present model-based study simulated the trajectory of
7300 HCV-seronegative HCWs (ie, number of HCWs percuta-
neously exposed to anti-HCV antibody-positive source patients
each year in France),
1 who were followed from exposure to
death. Model outcomes included the number of patients who
developed chronic hepatitis C (CHC), number of incidents of
CHC avoided by early therapy, lifetime quality-adjusted life
years (QALYs), direct medical costs and incremental C/E ratios.
The incremental C/E ratio was defined as the additional cost of
a specific strategy compared with the next least expensive
strategy, divided by its additional clinical benefit.
21 We adopted
a societal perspective considering everyone affected by the
intervention and counting all significant health outcomes and
costs that flow from it from the time of intervention to death.
21
Future costs and clinical benefits were discounted at 3% per
year.
21 Costs were expressed in 2006 Euros (J1.00=
US$1.34=£0.78, 17 October 2008).
Model structure
Follow-up strategies after occupational exposure
The decision tree simulated four follow-up strategies after
occupational exposures to HCV (Supplementary fig 1). The
trajectory of HCWs through each strategy is described in detail
in the legend of Supplementary fig 1. In brief, we modelled the
trajectory of the HCWs in such a way that we were first able to
estimate, based on the sensitivity of tests used for each strategy,
the time to HCV positivity detection for that strategy. Next, in
those in whom HCV transmission occurred, we were able to
model the probability of hepatitis C spontaneous resolution, the
benefit of treating acute hepatitis C earlier in the absence of the
spontaneous resolution of the infection and the course of CHC
disease in the absence of a response to acute hepatitis C
treatment.
Follow-up in the case where a treatment for acute hepatitis C was
initiated
Treatment for acute hepatitis C was administered for a duration
of 6 months.
22 A positive HCV RNA test at the end of
treatment corresponded to non-response to treatment and the
patient was considered to have CHC. For those with a negative
HCV RNA test at the end of treatment, HCV RNA was tested
again 6 months later. A positive test at that time corresponded
to a relapse and the patient was considered to have CHC,
whereas a negative test corresponded to a sustained viral
response (SVR). The follow-up of treatment for acute hepatitis
C consisted of three outpatients visits and three ALT measure-
ments at 1, 3 and 6 months after the start of therapy, one HCV
RNA test at the end of treatment and one 6 months later.
CHC disease course
Life expectancy, health-related quality of life and lifetime costs
of patients with CHC were estimated from the study of San
Miguel et al
23 where the course of HCV disease was modelled in
a cohort of Spanish patients with CHC, with a median age of 42
years, who had previously not responded to interferon (IFN).
We used a study in which the course of patients who had not
responded to antiviral therapy was modelled because in our
analysis all HCWs with CHC had failed a first antiviral
treatment for acute hepatitis C. In the study of San Miguel et
al, patients received an additional course of standard IFN and
ribavirin combination for 12 months and the course of the
disease was simulated until death.
Input data
HCV transmission probability
In the base case analysis, the average risk of HCV transmission
after occupational exposure considered was 0.5%.
11 17 In the
sensitivity analysis, a lower and a higher risk were considered.
We used data from a recent case–control study of risk factors for
HCV transmission to estimate the risk of HCV transmission
after occupational exposure according to the presence of one or
several risk factors.
18 We found that in the most favourable
cases, superficial injuries corresponded to a low risk of 0.009%,
whereas, in the least favourable, deep injuries with a hollow-
bore needle in a vein or artery of a male HCW corresponded to a
higher risk of 6.669%.
Test sensitivity and specificity
Test sensitivities were derived from knowledge of the time
interval from HCV exposure to: (1) the appearance of anti-HCV
antibodies with third-generation assays; (2) the elevation of
ALT; and (3) HCV RNA detection (table 1). The mean interval
to the appearance of anti-HCV antibodies was previously
estimated at 66 days
24 to 82 days.
25 26 Mosley et al reported that
the median latency period to an ALT elevation of .90 IU/l was
46 days.
27 The interval between ALT elevation and anti-HCV
antibody appearance is generally 1–2 weeks.
28 The interval from
HCV exposure to HCV RNA detection was reported to be 1–
2 weeks
29 with a mean of 10 days.
24 In this analysis, a normal
distribution was chosen to model the distribution of the times
to the appearance of anti-HCV antibodies and HCV RNA. An
exponential function was chosen to model the time to ALT
elevation, so that the cumulative probability of this elevation at
month 6 was ,1, taking into account the possible fluctuation of
ALT and the possible absence of detection of ALT elevation in
some subjects. The derived sensitivities increased from 10.2%
(range, 3.3–18.8%) at 1 month to 100% at 6 months for anti-
HCV antibodies, from 36.8% (36.8–44.3%) to 93.6% (93.6–
100%) for ALT, and were 100% for HCV RNA detection.
Specificities of 100% were assumed for anti-HCV antibody
30–32
and HCV RNA detection.
33 The specificity of the assay for ALT
was derived from a study conducted in a population of Japanese
male bank employees.
34 In that study, the specificity of elevated
ALT (.39 IU/l) was estimated at 86.3%.
Acute hepatitis C treatment efficacy
The French Haute Autorite ´ en Sante ´ (HAS) recommended
treating acute hepatitis C with standard IFN or pegylated
interferon monotherapy (PEG-IFN) (http://www.has-sante.fr/
portail/upload/docs/application/pdf/06-072_hepat-c_internet_-
sans_liste.pdf).
35 36 Recently, a randomised trial assessing the
efficacy and timing of PEG-IFN for treatment of acute hepatitis
C
36 has shown higher response rates with starting therapy at
weeks 8 or 12 versus week 20. Moreover, another study
assessing the efficacy, safety and optimal duration of PEG-IFN
treatment
22 has shown higher response rates with the 24 weeks
regimen. These studies have been used in our modelling to set
Hepatology
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treatment response (ETR) and SVR rate (table 2). Moreover, we
assumed that 26% of the subjects who seroconvert would
spontaneously clear HCV by the end of the third month, 26%
by the end of the fourth month, and 30% by the end of the sixth
month.
36
Health-related quality of life
The quality of life of the HCWs probably deteriorates during
the period of waiting for the detection tests to confirm or refute
transmission, because of the anxiety generated by the fear of
being infected, and was different among different strategies. In
addition, in those in whom HCV transmission occurred, life
expectancy and health-related quality of life were different
when compared with those in whom HCV transmission did not
occur.
As far as the quality of life of HCWs during the period of
waiting for the detection test is concerned, we first assumed
that the longer this period was, the more the quality of life will
deteriorate. The literature does not include any estimates of the
impact of the anxiety generated by the fear of being infected on
the quality of life. Rodger et al
37 examined the effect of diagnosis
of HCV infection on the quality of life of a cohort of patients
hospitalised with acute hepatitis 25 years ago. From this study,
Thein et al estimated the utilities (ie, recommended health-
related quality of life measure) associated with undiagnosed
asymptomatic CHC.
38 On the basis of these results, the utility
we assigned during the month after exposure to HCWs waiting
to be informed of their HCV status (ie, with undiagnosed
hepatitis C) was 0.86. We assumed that this figure would
increase by 0.04 for each month of waiting, and would reach
0.98 at 3 months after HCV exposure. We also assumed that
utilities would be higher in HCWs sustaining injuries carrying a
low risk of HCV transmission (0.90 at 1 month, 0.94 at month 2
and 0.98 thereafter), and lower in those sustaining injuries
carrying a high risk (0.82 at 1 month, 0.86 at month 2, 0.90 at
month 3, 0.94 at month 4 and 0.98 thereafter). For HCWs with
diagnosed hepatitis C, the utility was assumed to be 0.77.
HCWs with a negative HCV RNA test were assigned a utility
of 1.
Utilities during and after acute hepatitis C treatment with
PEG-IFN were based on the study of Thein et al
38: 0.82 during
the first 2 months, 0.81 during the following 2 months, and 0.79
during the last 2 months; utilities attributed to ETR and SVR
were 0.80 and 0.87, respectively. Average discounted quality-
adjusted life expectancy of a 42-year-old patient with CHC and
without CHC (ie, a healthy person) was at 12.44 and 21.77
QALYs, respectively.
23 Of note, the latest estimate matched the
discounted-adjusted life expectancy of a 42-year-old healthy
person in France (ie, 34 undiscounted years) (http://www.who.
int/whosis/database/life_tables/life_tables.cfm).
Costs
The costs of screening tests, outpatient visits, treatment of
acute hepatitis C, and treatment and follow-up of CHC for non-
responders and relapsers to early treatment in the acute phase
were taken into account in this analysis. For screening tests, the
following unit costs were obtained from the French
Nomenclature des Actes de Biologie Me ´dicale (Nomenclature
of medical biology acts) (available at http://www.ameli.fr/
professionnels-de-sante/directeurs-d-etablissements-de-sante/
index_savoie.php): J18.90 for anti-HCV antibody screening
(third-generation ELISA), J5.94 for ALT measurement and
J48.60 for HCV RNA detection. We assumed that HCWs
attended an outpatient visit at the time of exposure, during
follow-up when the HCV RNA was detected, before acute
hepatitis C treatment initiation, during treatment (at 1 month,
3 months and at the end of treatment) and 6 months after the
end of treatment for ETR and SVR. Doctors’ fees for an
outpatient consultation were obtained from the French
Nomenclature Ge ´ne ´rale des actes professionnels (General
nomenclature for professional acts) and estimated at J26.
Costs of 6 months PEG-IFN therapy for acute hepatitis C were
calculated as the average cost of a treatment schedule between
PEG-IFN alpha-2a and PEG-IFN alpha-2b (1.5 mg/kg per week):
J5841.51. Total discounted lifetime costs of treatment and
follow-up of CHC were from the study of San Miguel et al (ie,
J26 000, with costs inflated to 2006 Euros.
23
Sensitivity analysis
First, we considered a low (0.009%) and high (6.669%) risk of
HCV transmission after occupational exposure compared with
the average of 0.5%. Next, we evaluated the implications of
alternative assumptions in areas where we lacked primary data.
We varied the distribution of the appearance of anti-HCV
antibodies, ALT elevation and HCV RNA detection (table 1).
We varied HCWs’ monthly quality of life while waiting for their
HCV status over a wide range. We varied the proportion of the
subjects who spontaneously clear HCV during the acute phase:
between 20 and 30% at month 3 and 4, and between 26 and
35% at month 6. Finally, we varied the discounted cost of
treatment and follow-up of CHC between J13 000 and J52 00.
Software
The model was analysed with TreeAge Pro 2006 software
(Williamstown, Massachusetts, USA).
RESULTS
Baseline analysis
Assuming the baseline risk of HCV transmission after a
percutaneous injury, table 3 shows for a cohort of 7300
HCWs percutaneously exposed to HCV-positive source patients
each year in France and for each studied strategy, the direct
medical costs of follow-up, the mean time to HCV diagnosis,
the number of patients who developed CHC and the number of
CHC cases avoided by early therapy. The highest direct medical
Table 1 Time to appearance of anti-HCV antibodies, ALT elevation and
HCV RNA detection
Marker Estimates
Model in baseline
analysis
Models in
sensitivity analysis
Anti-HCV
antibodies
m=66 days
(SD=28);
24 82 days
(range, 54–192)
25
Normal distribution
(m=66; SD=28)
Normal distribution
(m=49; SD=21)
or Normal
distribution (m=82;
SD=28)
ALT Median at 46 days;
27 1–
2 weeks before HCV
seroconversion
28
Exponential
distribution
(l*=0.015)
Exponential
distribution (l=1/
52) or Exponential
distribution (l=1/
59)
HCV RNA m=10 days;
24 1–
2 weeks
29
Normal distribution
(m=10; SD=3.5)
Normal distribution
(m=7; SD=3.5) or
Normal distribution
(m=14; SD=7)
*l is the parameter of the exponential distribution which is equal to ln(2) divided by
the median time of elevation of ALT, which was set at 46 days in the base case
analysis.
27
ALT, alanine transaminase; HCV, hepatitis C virus; m, mean.
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Gut 2009;58:105–110. doi:10.1136/gut.2007.145516 107costs were obtained with the French strategy (J1 324 220 ) and
the lowest with the baseline-US strategy (J924 180). The times
to HCV infection diagnosis ranged from 1.0 for the alternative-
US strategy to 6.0 months for the baseline-US strategy. Thus,
the baseline-US strategy was the cheapest but was associated
with the longest time to HCV infection diagnosis. In contrast,
the alternative-US strategy was one of the most expensive but
was associated with the shortest time to diagnosis. Moreover, it
was associated with the lowest number of patients with CHC
(1.9 vs 7.9 for the baseline-US strategy) and the highest number
of CHC avoided by acute HCV treatment (25.1 vs 17.7 for the
baseline-US strategy).
Table 4 shows the incremental costs, utilities and incremental
C/E ratio for the baseline HCV transmission risk. Compared with
the alternative-US strategy, the French strategy was associated
with higher costs and lower utilities, and the European strategy
with a higher incremental C/E ratio. Compared with the baseline-
US strategy, the alternative-US strategy was associated with an
incremental C/E ratio of J2020 per QALY saved.
Sensitivity analysis
Table 5 shows the incremental costs, utilities and incremental
C/E ratio for low and high HCV transmission risk. When we
considered patients at low risk of HCV transmission, the C/E
ratio of the alternative-US strategy compared with the baseline-
US strategy was at J6102 per QALY saved. When the risk of
HCV transmission was high, the baseline-US strategy was no
longer the cheapest strategy because a higher number of CHC
cases, which are associated with high costs, occurred with this
strategy than with other strategies. The European strategy
became the cheapest strategy, and the C/E ratio of the
alternative-US strategy compared with the European strategy
was at J695 per QALY saved.
When we varied the health-related quality of life of HCWs,
while waiting for their HCV status and we assigned a utility of
0.99 per month (vs 0.86 at month 1, 0.90 at month 2, 0.94 at
month 3, and 0.98 thereafter in the base case analysis), first the
European strategy was no longer dominant and when compared
with the baseline-US strategy it was associated with a C/E ratio
of J3314 per QALY saved. Compared with the European
strategy, the alternative-US strategy was still associated with a
reasonable C/E ratio of J8069 per QALY saved. When we
assumed that waiting for HCV status had no impact on the
HCW’s quality of life (utilities at 1), compared with the
baseline-US strategy the C/E ratio of the European strategy was
estimated at J3958 per QALY saved. Compared with the
European strategy, the C/E ratio of the alternative-US strategy
was estimated at J234 000 per QALY saved.
Results were robust to variations in: (1) distributions used to
model the appearance of anti-HCV antibodies, ALT elevation
and HCV RNA detection; (2) in the proportion of the subjects
who spontaneously cleared HCV during the acute phase; and
(3) the cost of treatment and follow-up of CHC.
DISCUSSION
In this study, the cost and effectiveness of four strategies for
follow-up after occupational exposure to HCV were compared.
Although more expensive, a strategy based on early HCV RNA
testing was found to be associated with a reasonable C/E
ratio compared with strategies based on ALT detection and/or
Table 2 Proportion of end of treatment response (ETR) and sustained
viral response (SVR) with pegylated interferon during 6 months,
according to timing of therapy after exposure
36
Timing of therapy ETR (%) SVR (%)
Month 3 after exposure 95.3 93.2
Month 4 after exposure 91.8* 84.9*
Month 6 after exposure 84.8* 68.3*
*In the study of Kamal et al,
36 ETR and SVR were observed for patients starting
therapy at month 3 and month 5. We extrapolated ETR and SVR for patients starting
therapy at month 4 and month 6 from these data according to a linear function.
Table 3 Direct medical costs, mean time to HCV diagnosis, number of patients who developed CHC and
number of CHC cases avoided by early therapy, associated with different follow-up strategies in 7300 French
HCWs occupationally exposed to HCV
Strategy Costs* (J)
Mean time to HCV
diagnosis{ (months) No of CHC cases
No of CHC cases
avoided by acute HCV
treatment
French strategy based on anti-HCV
antibody and ALT monitoring (strategy
1)
1 324 220 2.2 2.0 24.9
European strategy based on ALT
monitoring (strategy 2)
1 132 230 2.0 2.1 24.9
Baseline-US strategy based on anti-HCV
antibody and ALT monitoring (strategy
3)
924 180 6.0 7.9 17.7
Alternative-US strategy based on HCV
RNA testing (strategy 4)
1 303 050 1.0 1.9 25.1
*Estimated costs from exposure to death.
{Mean time from exposure to HCV diagnosis.
ALT, alanine transaminase; CHC, chronic hepatitis C; HCV, hepatitis C virus; HCW, healthcare worker.
Table 4 Costs, QALYs and C/E ratios associated with four follow-up
strategies for HCWs occupationally exposed to HCV according to
average risk of HCV transmission
Strategy
Costs per HCW
(J) QALYs Incremental C/E ratio
Baseline-US 126.60 23.2292
European 155.10 23.2409 Weakly dominated*
Alternative-US 178.50 23.2549 J2020
French 181.40 23.2396 Strongly dominated{
*A weakly dominated strategy a higher incremental C/E ratio than that of a more
effective alternative strategy—that is, the incremental C/E ratio of the European
strategy vs the baseline-US is higher than the incremental C/E ratio of the alternative-
US strategy vs the European strategy.
{A strongly dominated strategy indicates a higher cost than that of a more effective
alternative strategy—that is, the French strategy is associated with a higher cost and
a lower utility compared with the alternative-US strategy.
C/E, cost-effectiveness; HCV, hepatitis C virus; HCW, healthcare worker; QALY,
quality-adjusted life year.
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transmission considered, the C/E ratio of this strategy was
lower than the ratio of US$50 000 (about J37 000, £29 000) per
QALY for dialysis for end-stage renal disease, often described as
a benchmark for C/E.
39 Moreover, the C/E of this strategy was
less than the Gross Domestic Product (GDP) per capita of France
in 2006 (ie, J30 000), designed as the threshold for considering
interventions as ‘‘very cost-effective’’.
40
Our results are first related to the fact that HCV RNA testing
may lead to earlier detection of acute hepatitis C when
compared with other strategies, and therefore to earlier
initiation of anti-HCV therapy. We tested the impact of earlier
diagnosis on the response to treatment, using data from the
study of Kamal et al.
36 This study showed that PEG-IFN therapy
induces high SVR rates and prevents CHC, and that SVR varied
according to timing of therapy.
36 Our analysis suggested that
the alternative-US strategy would lead to a slightly lower
number of CHC cases than the French and European strategies.
Moreover, it suggested that the alternative-US strategy would
lead to a much lower number of CHC cases than the baseline-
US strategy (1.9 vs 7.9 CHC among 7300 HCWs percutaneously
exposed to anti-HCV antibody-positive source patients).
Our results are also related to the impact of occupational
exposure on the health-related quality of life of HCWs. We
found that with the strategy based on early HCV RNA testing,
the absence of HCV transmission to HCWs could be confirmed
earlier than with the other strategies. As a result, HCW quality
of life deteriorated less, because the period of waiting for the
detection tests to confirm or refute transmission was shorter.
One of this study’s main limitations was the lack of data on the
quality of life of HCWs awaiting the results of detection tests.
We used utilities associated with undiagnosed asymptomatic
CHC as a substitute for estimating the quality of life of an
HCW exposed to an HCV-infected source patient. We noted
with interest that our conclusions were robust over a wide
range of values for quality of life of HCWs during sensitivity
analysis. In particular, an early HCV RNA testing strategy was
associated with a reasonable C/E ratio even when we considered
that the quality of life of an HCW was very moderately
modified while they were waiting for their HCV status after an
exposure. The HCV RNA testing strategy was not more cost-
effective only when we assumed that the quality of life of an
HCW was not modified at all while they were waiting for their
HCV status, which is unlikely.
In the present analysis, we did not take into account the fact
that a large proportion of HCWs are lost to follow-up during the
period after occupational exposure. However, the longer the
follow-up period until the detection of HCV transmission, the
greater the probability of loss to follow-up. The proportion of
patients lost to follow-up is therefore probably lower with a
strategy based on early HCV RNA testing. Again, if we had
incorporated losses to follow-up in our analysis, early HCV RNA
testing would probably have been even more cost-effective.
Finally, we did not consider the costs of the time lost by HCWs
who had to attend outpatient visits. However, all these costs
weigh heavier for Strategies 1, 2 and 3 than for Strategy 4. If we
had included them in the analyses, HCV RNA testing would have
been even more cost-effective and perhaps even cost-saving.
In conclusion, in HCWs exposed to HCV, a strategy based on
HCV RNA testing leads to earlier detection of HCV transmis-
sion. It is therefore proposed that anti-HCV therapy should take
place earlier in these patients than with other strategies, which
would result in a lower risk of progression to CHC. Moreover, a
strategy based on HCV RNA testing leads to earlier confirma-
tion of the absence of HCV transmission than other strategies,
and therefore shortens the period during which the HCW’s
quality of life deteriorates. We found that although the HCV
RNA testing strategy is more expensive than the other strategies
examined, it is reasonably cost-effective for all the risks of HCV
transmission considered. We therefore recommend its use for
occupational HCV detection.
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